Abstract | OBJECTIVE: METHODS: This was a randomized controlled trail. Total 591 ACS patients with DM who underwent percutaneous coronary intervention were enrolled, 297 in high intensity atorvastatin group (40mg/day) and 294 in moderate intensity atorvastatin group (20mg/day). The primary end point was one-year incidence of major adverse cardiovascular events ( MACE, including cardiovascular death, spontaneous myocardial infarction, unplanned revascularization). Cox proportional hazard regression models were used to analyze the association between clinical endpoints and atorvastatin treatment. RESULTS: At the end of one-year, low-density lipoprotein cholesterol level was lower in high intensity group than in moderate group (1.6±0.6 vs 1.8±0.6, p=0.041). MACE in high intensity group decreased 44.5% than moderate group (8.4% vs. 14.6%, p=0.018). The adjusted hazard ratio (HR) for MACE in patients with atorvastatin 40mg/d was lower compared to patients with atorvastatin 20mg/d (HR [95% CI] 0.61 [0.36 to 0.91], p=0.026). The rates of adverse events were no significantly different between the two groups. CONCLUSIONS: For ACS patients with DM, high intensity atorvastatin induced better long-term outcomes compared with moderate intensity.
|
Authors | Zhi Liu, Yueqiao Xu, Hengjian Hao, Chunlin Yin, Ji Xu, Jing Li, Yanling Wang, Dong Xu |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 222
Pg. 22-26
(Nov 01 2016)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 27448700
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2016 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Atorvastatin
|
Topics |
- Acute Coronary Syndrome
(complications, diagnosis, drug therapy)
- Aged
- Atorvastatin
(administration & dosage, adverse effects)
- Diabetes Mellitus, Type 2
(complications)
- Dose-Response Relationship, Drug
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(administration & dosage, adverse effects)
- Long Term Adverse Effects
(diagnosis, epidemiology, mortality)
- Male
- Middle Aged
- Percutaneous Coronary Intervention
(methods)
- Prognosis
- Proportional Hazards Models
- Treatment Outcome
|